![Per Grufman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Per Grufman
Algemeen Directeur bij BioCrucible Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Niall Antony Armes | M | 54 |
BioCrucible Ltd.
![]() BioCrucible Ltd. BiotechnologyHealth Technology Part of Sapphiros, BioCrucible Ltd. is a British company that develops high-performance molecular consumer diagnostics. The company is based in Cambridge, UK. BioCrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications. The company was founded in 2018 by Niall Antony Armes. Per Grufman has been the CEO of the company since January 20, 2023. BioCrucible was acquired by Sapphiros on July 21, 2021. | - |
Ali Satvat | M | 46 |
BioCrucible Ltd.
![]() BioCrucible Ltd. BiotechnologyHealth Technology Part of Sapphiros, BioCrucible Ltd. is a British company that develops high-performance molecular consumer diagnostics. The company is based in Cambridge, UK. BioCrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications. The company was founded in 2018 by Niall Antony Armes. Per Grufman has been the CEO of the company since January 20, 2023. BioCrucible was acquired by Sapphiros on July 21, 2021. | - |
Anuv Ratan | M | - |
BioCrucible Ltd.
![]() BioCrucible Ltd. BiotechnologyHealth Technology Part of Sapphiros, BioCrucible Ltd. is a British company that develops high-performance molecular consumer diagnostics. The company is based in Cambridge, UK. BioCrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications. The company was founded in 2018 by Niall Antony Armes. Per Grufman has been the CEO of the company since January 20, 2023. BioCrucible was acquired by Sapphiros on July 21, 2021. | - |
David Graham Brooks | M | 56 |
BioCrucible Ltd.
![]() BioCrucible Ltd. BiotechnologyHealth Technology Part of Sapphiros, BioCrucible Ltd. is a British company that develops high-performance molecular consumer diagnostics. The company is based in Cambridge, UK. BioCrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications. The company was founded in 2018 by Niall Antony Armes. Per Grufman has been the CEO of the company since January 20, 2023. BioCrucible was acquired by Sapphiros on July 21, 2021. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 4 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Per Grufman
- Persoonlijk netwerk